Discovering Anti-Cancer Drugs via Computational Methods

被引:197
作者
Cui, Wenqiang [1 ,2 ]
Aouidate, Adnane [1 ]
Wang, Shouguo [1 ]
Yu, Qiuliyang [1 ]
Li, Yanhua [2 ]
Yuan, Shuguang [1 ]
机构
[1] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China
[2] Northeast Agr Univ, Coll Vet Med, Harbin, Peoples R China
关键词
anti-cancer; CADD; drug discovery; AI; computational methods; SUPERVISED MOLECULAR-DYNAMICS; GROWTH-FACTOR RECEPTOR; TARGET INTERACTION PREDICTION; PROTEIN-COUPLED RECEPTORS; C-MET; PHARMACOPHORE MODEL; NEURAL-NETWORKS; INHIBITOR; CANCER; HSP90;
D O I
10.3389/fphar.2020.00733
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
New drug discovery has been acknowledged as a complicated, expensive, time-consuming, and challenging project. It has been estimated that around 12 years and 2.7 billion USD, on average, are demanded for a new drug discovery via traditional drug development pipeline. How to reduce the research cost and speed up the development process of new drug discovery has become a challenging, urgent question for the pharmaceutical industry. Computer-aided drug discovery (CADD) has emerged as a powerful, and promising technology for faster, cheaper, and more effective drug design. Recently, the rapid growth of computational tools for drug discovery, including anticancer therapies, has exhibited a significant and outstanding impact on anticancer drug design, and has also provided fruitful insights into the area of cancer therapy. In this work, we discussed the different subareas of the computer-aided drug discovery process with a focus on anticancer drugs.
引用
收藏
页数:14
相关论文
共 134 条
[1]   Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer [J].
Al-Salama, Zaina T. .
DRUGS, 2019, 79 (14) :1591-1598
[2]   Entrectinib: First Global Approval [J].
Al-Salama, Zaina T. ;
Keam, Susan J. .
DRUGS, 2019, 79 (13) :1477-1483
[3]  
[Anonymous], 1964, J. Am. Chem. Soc, DOI DOI 10.1021/JA01078A623
[4]  
Anthony CS, 2012, CURR MED CHEM, V19, P845
[5]   Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial [J].
Atkins, Michael B. ;
Plimack, Elizabeth R. ;
Puzanov, Igor ;
Fishman, Mayer N. ;
McDermott, David F. ;
Cho, Daniel C. ;
Vaishampayan, Ulka ;
George, Saby ;
Olencki, Thomas E. ;
Tarazi, Jamal C. ;
Rosbrook, Brad ;
Fernandez, Kathrine C. ;
Lechuga, Mariajose ;
Choueiri, Toni K. .
LANCET ONCOLOGY, 2018, 19 (03) :405-415
[6]  
Beghi E, 2019, LANCET NEUROL, V18, P357, DOI [10.1016/S1474-4422(19)30034-1, 10.1016/S1474-4422(18)30454-X, 10.1016/S1474-4422(18)30443-5]
[7]   Duvelisib: First Global Approval [J].
Blair, Hannah A. .
DRUGS, 2018, 78 (17) :1847-1853
[8]  
BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/bf00124387
[9]   Virtual and biomolecular screening converge on a selective agonist for GPR30 [J].
Bologa, CG ;
Revankar, CM ;
Young, SM ;
Edwards, BS ;
Arterburn, JB ;
Kiselyov, AS ;
Parker, MA ;
Tkachenko, SE ;
Savchuck, NP ;
Sklar, LA ;
Oprea, TI ;
Prossnitz, ER .
NATURE CHEMICAL BIOLOGY, 2006, 2 (04) :207-212
[10]  
Born J., 2019, PACCMANNRL DESIGNING